Quercis Pharma is focused on developing innovative treatments for life-threatening conditions through its proprietary platforms, particularly in the areas of anti-thrombotic, anti-cancer, antiviral, and immuno-modulatory therapies. The company’s lead drug candidate, Kinisoquin™, is based on a patented formulation of Isoquercetin, which has demonstrated the ability to prevent platelet activation and the initiation of the thrombotic cascade. This novel mechanism of action aims to effectively prevent venous thromboembolism (VTE) in high-risk cancer patients without the increased bleeding risk associated with current anticoagulants. Quercis Pharma is also exploring the potential of its PDI inhibitors in cancer treatment and the relationship between viral illnesses and thrombosis, indicating a broad scope of research aimed at addressing significant unmet medical needs.

In addition to its primary focus on VTE prevention in cancer patients, Quercis Pharma is investigating the use of Kinisoquin™ for other conditions, including sickle cell disease and amyotrophic lateral sclerosis (ALS). The company emphasizes a commitment to safety, with clinical trials showing no serious side effects or increased bleeding risk from its investigational drugs. Quercis Pharma aims to make its treatments accessible to impoverished populations worldwide, planning to offer medications at significantly reduced prices. This humanitarian approach reflects the company's belief in addressing global health challenges and improving healthcare access for vulnerable communities.

Switzerland

Quercis Pharma AG is leveraging its novel antithrombotic platform to deliver safe and innovative treatments to patients with a variety of complex diseases that are poorly addressed by today’s medicines and is committed to providing affordable access to these potentially life-saving therapies

Quercis Pharma

Company Details